Twist Bioscience (NASDAQ:TWST) Price Target Raised to $43.00

Twist Bioscience (NASDAQ:TWST) had its price target increased by TD Cowen from $32.00 to $43.00 in a research report sent to investors on Thursday morning,Benzinga reports. They currently have a buy rating on the stock.

A number of other analysts have also commented on TWST. Stephens assumed coverage on Twist Bioscience in a research report on Monday, November 3rd. They issued an “overweight” rating and a $41.00 price objective for the company. Barclays raised their price objective on shares of Twist Bioscience from $37.00 to $39.00 and gave the company an “overweight” rating in a research note on Monday, December 15th. Evercore ISI restated an “outperform” rating and set a $42.00 target price on shares of Twist Bioscience in a research report on Monday, January 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Twist Bioscience in a report on Monday, December 29th. Finally, Cowen reiterated a “buy” rating on shares of Twist Bioscience in a report on Thursday. Nine investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat, Twist Bioscience presently has an average rating of “Moderate Buy” and a consensus price target of $44.67.

Twist Bioscience Price Performance

TWST opened at $35.32 on Thursday. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.64 and a quick ratio of 3.33. The stock has a market capitalization of $2.16 billion, a P/E ratio of -26.96 and a beta of 2.19. The company’s 50 day simple moving average is $31.49 and its 200-day simple moving average is $31.14. Twist Bioscience has a one year low of $23.30 and a one year high of $55.33.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings data on Friday, November 14th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.05). The firm had revenue of $99.01 million for the quarter, compared to analyst estimates of $97.40 million. Twist Bioscience had a negative return on equity of 27.40% and a negative net margin of 20.63%. Sell-side analysts anticipate that Twist Bioscience will post -2.12 earnings per share for the current fiscal year.

Insider Buying and Selling at Twist Bioscience

In other news, CEO Emily M. Leproust sold 31,379 shares of the firm’s stock in a transaction that occurred on Thursday, October 30th. The shares were sold at an average price of $31.44, for a total transaction of $986,555.76. Following the completion of the transaction, the chief executive officer directly owned 738,809 shares of the company’s stock, valued at $23,228,154.96. This trade represents a 4.07% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Paula Green sold 6,920 shares of Twist Bioscience stock in a transaction that occurred on Thursday, October 30th. The shares were sold at an average price of $31.44, for a total transaction of $217,564.80. Following the completion of the sale, the senior vice president owned 143,271 shares in the company, valued at $4,504,440.24. This trade represents a 4.61% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 60,699 shares of company stock valued at $1,919,823 in the last 90 days. 3.01% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in TWST. Quarry LP acquired a new stake in Twist Bioscience in the 3rd quarter valued at $28,000. Smartleaf Asset Management LLC boosted its stake in shares of Twist Bioscience by 70.6% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,068 shares of the company’s stock worth $29,000 after buying an additional 442 shares during the last quarter. National Bank of Canada FI bought a new position in shares of Twist Bioscience in the 3rd quarter valued at about $46,000. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Twist Bioscience by 15.0% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,315 shares of the company’s stock valued at $85,000 after acquiring an additional 302 shares during the last quarter. Finally, Geneos Wealth Management Inc. acquired a new stake in shares of Twist Bioscience in the second quarter valued at about $97,000.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.